116666-63-8
基本信息
鹽酸米貝地爾
鹽酸米貝拉地爾
米貝拉地爾二鹽酸鹽
MIBEFRADIL
(1s-cis)-orid
ro40-5967/001
Mibefradil HCl
Mibefradil 2HCl
Mibefradil diHCl
Ro 40-5967 hydrate
MIBEFRADIL USP/EP/BP
Mibefradil(Ro 40-5967)
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見(jiàn)問(wèn)題列表
IC50: 2.7 μM (T-type calcium channel), 18.6 μM (L-type calcium channel)
Mibefradil dihydrochloride inhibits reversibly the T- and L-type currents with IC 50 values of 2.7 and 18.6 μM, respectively. The inhibition of the L-type current is voltage-dependent, whereas that of the T-type current is not. Ro 40-5967 blocks T-type current already at a holding potential of -100 mV At a higher concentration (20 μM), Mibefradil reduces the amplitude of excitatory junction potentials (by 37±10 %), slows the rate of repolarisation (by 44±16 %) and causes a significant membrane potential depolarisation (from ?83±1 mV to ?71±5 mV). At a higher Mibefradil concentration (20 μM) there is significant membrane potential depolarisation and a slowing of repolarisation. These actions of Mibefradil are consistent with K + channel inhibition, which has been shown to occur in human myoblasts and other cells.
The hearing thresholds of the 24-26 week old C57BL/6J mice differ following the 4-week treatment period. The hearing threshold at 24 kHz is significantly decreased in the Mibefradil-treated and benidipine-treated groups compared with the saline-treated group (P<0.05). Compared with the saline-treated group, rats receiving Mibefradil or NSC 64013 show significant lower Ca V 3.2 expression in the spinal cord and DRG.